Welcome, Guest. Please login or register.
June 25, 2019, 10:17:31 pm

Login with username, password and session length

  • Total Posts: 745585
  • Total Topics: 62329
  • Online Today: 312
  • Online Ever: 1421
  • (August 13, 2016, 05:18:44 am)
Users Online
Users: 5
Guests: 258
Total: 263


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: More Good Marks for Janssenís New HIV Regimen Symtuza  (Read 434 times)

0 Members and 1 Guest are viewing this topic.

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 12,332
  • Twitter @JimAllenDublin
    • HIV Lessons
More Good Marks for Janssenís New HIV Regimen Symtuza
« on: November 01, 2018, 03:09:37 am »


Janssenís newly approved antiretroviral regimen Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) is safe and effective after 96 weeks of treatment among people starting HIV treatment for the first time.

Presenting their findings at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow), researchers conducted a randomized, double-blind, active-controlled, international multicenter noninferiority Phase III trial called AMBER. The trial randomly assigned 362 people to start treatment with Symtuza and 363 people to start treatment with Prezcobix (darunavir/cobicistat) plus Truvada (tenofovir disoproxil fumarate/emtricitabine).

Forty-eight week results from AMBER were previously presented at the 16thEuropean AIDS Conference in Milan in November 2017.

At week 96, among those who received Symtuza, 85 percent (308 of 362) had a fully suppressed virus at that time and 6 percent (20 of 362) had ever experienced a viral load above 50 during the study.

No one in the study developed viral mutations associated with Prezista (darunavir), their primary protease inhibitors or tenofovir. Through 96 weeks, two participants in the Symtuza arm developed a resistance-associated mutation, known as M184I/V, to Emtriva (emtricitabine).

Symtuza was well tolerated, with 11 percent (39 people) experiencing serious adverse health events and 3 percent (10 people) discontinuing treatment due to adverse health events. The treatmentís safety profile for bone, kidney and blood lipids was consistent with what is known about the safety profiles of tenofovir and Tybost (cobicistat), including a small change in the total cholesterol to HDL cholesterol ratio.

All told, the safety and efficacy results for Symtuza at 96 weeks were consistent with those seen at 48 weeks.
HIV 101 - Everything you need to know
HIV 101
Transmission and Risks:
HIV Transmission and Risks
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP


Terms of Membership for these forums

© 2019 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.